NurExone Announces Appointment of New Director and Provides Corporate Updates
Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons.Dr. Riesenfeld has served on the board of directors and as president of several bio-pharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., and...
2023-07-07 9:23 AM EDT
NurExone Engages Investor Relations Service Provider
Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC ("Litchfield") to perform investor relations services and activities, as defined in accordance with the policies of the TSX Venture Exchange...
2023-05-12 8:00 AM EDT
NurExone Announces Equity Incentive Plan Grants and Director Resignation
Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options ("Options") and 1,275,000 restricted share units ("RSUs") under the Company's equity incentive plan to certain officers and directors of the...
2023-05-08 8:51 AM EDT
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone
Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application NO. 17/042,441 ("the Patent"). The Patent covers and protects NurExone Exo-PTEN...
2023-01-12 8:51 AM EST
NurExone Issues Annual Shareholder Letter
Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from NurExone CEO Dr. Lior Shaltiel.Dear Shareholders, We started our journey to provide much-needed therapy for people who have suffered spinal cord...
2022-12-15 8:30 AM EST
NurExone Announces Completion of Securites for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for debt settlement on December 6, 2022, previously announced by the Company on November 24, 2022. The Company agreed to settle debts in the aggregate...
2022-12-07 6:17 PM EST
Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error.Calgary, Alberta--(Newsfile Corp. - December 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported today results of a pre-clinical loading efficiency...
2022-12-01 2:30 PM EST
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology has the potential to serve as an efficient process for...
2022-11-30 8:30 AM EST
NurExone Announces Securities for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at a deemed price of CAD$0.38 per share.These debts were incurred...
2022-11-24 7:17 PM EST
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter ended September 30, 2022."Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working...
2022-11-24 8:00 AM EST
NurExone Announces Completion of Securities for Debt Settlements
Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by the Company on September 1, 2022 and September 19, 2022. The Company agreed to settle debts in the...
2022-11-08 5:01 PM EST
NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration
IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into the U.S. market.Calgary, Alberta--(Newsfile Corp. - November 2, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased...
2022-11-02 8:00 AM EDT
NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production
Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced today results of an internal productivity and quality pilot that was completed by the Company and the Technion - Israel Institute of Technology in Q2 2022 pursuant to the previously announced Sponsor Research...
2022-10-26 9:00 AM EDT
NurExone Biologic to Participate in 2022 Bio-Europe Conference
Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company will be participating in the upcoming 2022 Bio-Europe Conference ("Bio-Europe") in Leipzig, Germany, which commences on October 24th and ends on October 26th.Bio-Europe is regarded as one of Europe's...
2022-10-20 8:00 AM EDT
UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology
Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company's wholly-owned subsidiary, NurExone Biologic Ltd., signed a non-binding...
2022-10-12 12:55 PM EDT
NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology
Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company's wholly-owned subsidiary, NurExone Biologic Ltd., signed a non-binding...
2022-10-12 9:00 AM EDT
NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company's lab showing the effectiveness of the Company's proprietary small interfering RNA (siRNA) in inhibiting the expression of the phosphatase and tensin homolog...
2022-10-04 9:00 AM EDT
NurExone Announces Additional Securities for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - October 3, 2022) - Further to our news release of September 1, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is announcing today that it has agreed to settle additional debts in the amount of CAD$75,000 with the issuance of 178,571 common shares of the...
2022-10-03 5:00 PM EDT
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is pleased to announce that the Company has entered into a letter of intent (the "Letter of Intent") with denovoMATRIX GmbH, a leading German-based developer of innovative technologies which enable cell therapies...
2022-09-07 8:30 AM EDT
NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar's Debts Prior to RTO Transaction
Calgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed price of CAD$0.80 per share to settle indebtedness of CAD$136,155.83 owed to certain senior officers, directors, creditors,...
2022-09-01 8:00 AM EDT